Mid-regional pro-adrenomedullin and lactate dehydrogenase as predictors of left ventricular remodeling in patients with myocardial infarction treated with percutaneous coronary intervention

Węgiel, Michał; Wojtasik-Bakalarz, Joanna; Malinowski, Krzysztof Piotr; Surmiak, Marcin; Dziewierz, Artur; Sorysz, Danuta; Tokarek, Tomasz; Dudek, Dariusz; Bartuś, Stanisław; Surdacki, Andrzej; Rakowski, Tomasz

doi:10.20452/pamw.16150

Cited by 10 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure 5D , exosome miR-874-3p exhibited a positive correlation with LDH ( p < 0.05, r = 0.50). It was found that the serum levels of LDH served as a predictor of adverse LV remodeling in a former study ( 23 ). As shown in Figure 5E , levels of LDH were positively associated with NT-proBNP ( p < 0.01, r = 0.62) in patients with STEMI after 3–6 months.…”

Section: Resultsmentioning

confidence: 96%

Plasma Exosome miRNAs Profile in Patients With ST-Segment Elevation Myocardial Infarction

Guan

Zeng

Zhang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundCirculating microRNAs (miRNAs) have been found to have different expressions in different phases of acute myocardial infarction. The profiles of plasma exosome miRNAs in patients with ST-segment elevation myocardial infarction (STEMI) at 3–6 months postinfarction are unknown.ObjectiveThe aim of this study was to assess the profiles of plasma exosome miRNAs in patients with STEMI in comparison with healthy volunteers and to select specific exosome miRNAs related to pathophysiological changes post-STEMI.MethodsPlasma and echocardiography parameters were collected from 30 patients 3–6 months after STEMI and 30 healthy volunteers. Plasma exosome miRNAs were assessed by using high-throughput sequence (Illumina HiSeq 2500) and profile of the plasma exosome miRNAs was established in 10 patients and 6 healthy volunteers. The specific exosome miRNAs related to heart diseases were selected according to the TargetScan database. The specificity of the selected exosome miRNAs was evaluated in additional 20 post-STEMI patients and 24 healthy volunteers by using quantitative PCR (qPCR). Left ventricular remodeling (LVR) was defined using the European Association of Cardiovascular Imaging criteria according to echocardiography examination. Correlations between expression of the specific miRNAs and echocardiography parameters of LVR were assessed using the Spearman correlation analysis.ResultsTwenty eight upregulated miRNAs and 49 downregulated miRNAs were found in patients 3–6 months after STEMI (p < 0.01) in comparison with the healthy volunteers. The two least expressed and heart-related exosome miRNAs were hsa-miR-181a-3p (0.64-fold, p < 0.01) and hsa-miR-874-3p (0.50-fold, p < 0.01), which were further confirmed by using qPCR and demonstrated significant specificity in another 20 patients with post-STEMI comparing to 24 healthy volunteers [area under the curve (AUC) = 0.68, p < 0.05; AUC = 0.74, p < 0.05]. The expression of hsa-miR-181a-3p was downregulated in patients with LV adverse remodeling in comparison with patients without LV adverse remodeling and healthy volunteers.ConclusionCirculating exosome miR-874-3p and miR-181a-3p were downregulated in patients with STEMI postinfarction. Exosome hsa-miR-181a-3p might play a potential role in the development of LVR in patients with post-STEMI.

show abstract

Section: Resultsmentioning

confidence: 96%

Plasma Exosome miRNAs Profile in Patients With ST-Segment Elevation Myocardial Infarction

Guan

Zeng

Zhang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…However, the assessment of mid-regional proadrenomedullin (MR-proADM), a precursor molecule of ADM with greater stability, is feasible [ 52 , 53 ]. A recent prospective study that evaluated the relationship between MR-proADM and the left ventricular function after an MI concluded that this biomarker is an independent positive predictor of adverse remodeling, one of the main causes of heart failure, and a negative marker of reverse remodeling [ 55 ]. The Danish Study of Optimal Acute Treatment of Patients With STEMI (DANAMI-3) found that high MR-proADM levels (≥0.79 nmol/L) prior to PCI in patients with STEMI were strongly associated with an elevated risk of short- and long-term all-cause or cardiovascular mortality and hospital admission for heart failure [ 56 ].…”

Section: Resultsmentioning

confidence: 99%

From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction

Stătescu

Anghel

Tudurachi

et al. 2022

IJMS

View full text Add to dashboard Cite

Despite all the important advances in its diagnosis and treatment, acute myocardial infarction (AMI) is still one of the most prominent causes of morbidity and mortality worldwide. Early identification of patients at high risk of poor outcomes through the measurement of various biomarker concentrations might contribute to more accurate risk stratification and help to guide more individualized therapeutic strategies, thus improving prognoses. The aim of this article is to provide an overview of the role and applications of cardiac biomarkers in risk stratification and prognostic assessment for patients with myocardial infarction. Although there is no ideal biomarker that can provide prognostic information for risk assessment in patients with AMI, the results obtained in recent years are promising. Several novel biomarkers related to the pathophysiological processes found in patients with myocardial infarction, such as inflammation, neurohormonal activation, myocardial stress, myocardial necrosis, cardiac remodeling and vasoactive processes, have been identified; they may bring additional value for AMI prognosis when included in multi-biomarker strategies. Furthermore, the use of artificial intelligence algorithms for risk stratification and prognostic assessment in these patients may have an extremely important role in improving outcomes.

show abstract

“…This study showed that repeated measurements with 6-h lapses yielded increasing MR-proADM in the acute phase of STEMI [ 8 ]. Higher MR-proADM level during acute phase of STEMI was an independent predictor of adverse left ventricular remodeling among PCI-treated STEMI patients [ 12 ]. Furthermore, higher MR-proADM was an adverse predictor for improvement of left ventricular function or reverse remodeling after STEMI [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Higher MR-proADM level during acute phase of STEMI was an independent predictor of adverse left ventricular remodeling among PCI-treated STEMI patients [ 12 ]. Furthermore, higher MR-proADM was an adverse predictor for improvement of left ventricular function or reverse remodeling after STEMI [ 12 ]. Our study corroborated these previous studies and showed that MR-proADM increased in the acute phase of STEMI and steeply decreased in the recovery phase after 30 days.…”

Section: Discussionmentioning

confidence: 99%

High Level of Mid-Regional Proadrenomedullin during ST-Segment Elevation Myocardial Infarction Is an Independent Predictor of Adverse Cardiac Events within 90-Day Follow-Up

2022

View full text Add to dashboard Cite

Background and Objectives: the cardiovascular adverse events including mortality and heart failure, persist significantly during the first months after the acute phase of ST-segment elevation myocardial infarction (STEMI). The increased level of midregional proadrenomedullin (MR-proADM), at hospital presentation in STEMI patients is considered an independent predictor of short-term and long-term mortality and heart failure. This study aimed to measure MR-proADM levels during the acute and recovery phases of STEMI and corroborate whether MR-proADM level was associated with the adverse cardiac events after recovering from STEMI. Materials and Methods: this prospective study enrolled subjects with acute phase STEMI admitted to the intensive cardiac care unit. After recovering and discharged from hospitalization, subjects were followed-up for 90 days. For MR-proADM measurement, the blood samples during acute phase were withdrawn on hospital admission (MR-proADM-0) and during recovery at the day-30 follow up (MR-proADM-30). Adverse cardiac events were evaluated at 30-day and 90-day follow up, namely a composite of death, chronic heart failure, and hospital readmission of any cardiac causes. Results: 83 subjects were enrolled. The median MR-proADM-0 was 3313.33 pg/mL and MR-proADM-30 was significantly reduced at 292.50 pg/mL, p < 0.001. Nineteen subjects (22.9%) experienced adverse cardiac events at 30-day follow up. The MR-proADM-0 level was independently associated with 30-day adverse cardiac events (adjustedOR 1.002, 95%CI: 1.001–1.003, p = 0.040), after adjustment with other variables. In this case, 25 subjects (32.5%) experienced adverse cardiac events at 90-day follow-up. The MR-proADM-0 level was independently associated with 90-day adverse cardiac events (adjustedOR 1.002, 95%CI: 1.001–1.003, p = 0.049). The higher changes of MR-proADM-0 to MR-proADM-30 also associated with adverse cardiac events at 90 days. Conclusions: The MR-proADM was significantly increased during the acute phase of STEMI and declined during recovery phase. The higher MR-proADM level during the acute phase of STEMI and its change intensity were predictors of adverse cardiac events within the 90-day follow up.

show abstract

Mid-regional pro-adrenomedullin and lactate dehydrogenase as predictors of left ventricular remodeling in patients with myocardial infarction treated with percutaneous coronary intervention

Cited by 10 publications

References 26 publications

Plasma Exosome miRNAs Profile in Patients With ST-Segment Elevation Myocardial Infarction

Plasma Exosome miRNAs Profile in Patients With ST-Segment Elevation Myocardial Infarction

From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction

High Level of Mid-Regional Proadrenomedullin during ST-Segment Elevation Myocardial Infarction Is an Independent Predictor of Adverse Cardiac Events within 90-Day Follow-Up

Contact Info

Product

Resources

About